  PD-L1 and PD-1 inhibitors were both developed to combat a huge array of cancers. Both classes of agents block the PD-1/ PD-L1 pathway. Unlike PD-1 inhibitors , PD-L1 inhibitors do also block the B-7.1-receptor and leave the PD-L2/ PD-1 axis unaffected. Whether these differences enhance efficacy and tolerability is not clear yet. There are three PD-L1 inhibitors approved or in late clinical development: Atezolizumab , approved in 2